Skip to content
← Full study record

NCT01239368 · MORE INFO

Limitations, agreements, and source contact

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma · Source last updated 2019-12-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
3/34 pts signed consent but never received therapy due to progressive malignancy that precluded their ability to receive the experimental therapy. These participants were not assigned to a cohort.
point Of Contact
email
steven_pavletic@nih.gov
organization
National Cancer Institute
phone
301-402-4899
title
Dr. Steven Pavletic
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
3/34 pts signed consent but never received therapy due to progressive malignancy that precluded their ability to receive the experimental therapy. These participants were not assigned to a cohort.
point Of Contact
email
steven_pavletic@nih.gov
organization
National Cancer Institute
phone
301-402-4899
title
Dr. Steven Pavletic

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice